|
Dear Reader :
This month’s edition of Citeline’s newsletter, co-developed with the IPA, has a lot on the menu including the now and next pertaining to M&A in the US and opportunities in women’s health.
We bring you expert opinion on what the US FTC’s oversight of the Amgen/Horizon deal may mean for biopharma deal-making, while Ferring’s US CSO talks about the ‘vicious circle’ in women’s health investment.
Plus, there’s a fascinating piece on AI in cough diagnosis and management.
Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA
|
